Spero Therapeutics, Inc.
About Spero Therapeutics, Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $12.6M
- Net income
- $8.6M
- Total assets
- $68.9M
- Market cap
- $163.3M
- Operating margin
- 9.5%
- Net margin
- 12.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $66.8M
- Operating expenses
- $60.5M
- Operating income
- $6.3M
- Income tax
- $261.0K
- Net income
- $8.6M
- EPS (basic)
- $0.15
- EPS (diluted)
- $0.15
Balance sheet
- Total assets
- $68.9M
- Current assets
- $67.3M
- Total liabilities
- $9.9M
- Current liabilities
- $8.9M
- Shareholders’ equity
- $59.0M
Cash flow
- Operating cash flow
- -$12.6M
- Net cash flow
- -$12.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $163.3M
- P/E ratio
- 18.3
- EPS (diluted)
- $0.15
- Shares outstanding
- 59.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 2, 2017
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $8.6M in FY2025.
- Revenue grew 266% from FY2021 to FY2025.
- Trading 10% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 18.3.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Spero Therapeutics, Inc..
Write a review
News about Spero Therapeutics, Inc.
News & sentiment via Polygon.io
